ArticleOncotarget2016

Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.

Milica Stefanovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.